수의 종양학 시장 규모, 점유율, 성장 분석 : 요법 유형별, 동물 유형별, 암 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Veterinary Oncology Market size was valued at USD 290.79 Billion in 2024 and is poised to grow from USD 325.97 Billion in 2025 to USD 812.88 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

Veterinary oncology is experiencing significant market growth driven by an increase in cancer incidence among pets and a heightened demand for veterinary cancer treatments. Pet owners are increasingly investing in animal healthcare, fueled by initiatives aimed at improving veterinary oncology. In developed countries, spending on animal healthcare is on the rise, and the prevalence of neoplastic diseases in pets underlines the urgent need for better oncology treatments. Additionally, an upswing in veterinary clinical trials evaluating oncologic therapies further supports market expansion, with resources like the AVMA Animal Health Research Database aiding research efforts. The pet humanization trend is promoting closer bonds between owners and their pets, leading to increased pet adoption and healthcare spending, ultimately boosting the veterinary oncology market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Veterinary Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Veterinary Oncology Market Segments Analysis

Global Veterinary Oncology Market is segmented by therapy type, animal type, cancer type, end-user and region. Based on therapy type, the market is segmented into chemotherapy, radiation therapy, immunotherapy and surgery. Based on animal type, the market is segmented into companion animals and livestock animals. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer and others. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Veterinary Oncology Market

The increasing occurrence of cancer among companion animals, particularly dogs and cats, significantly propels the veterinary oncology market. As pets enjoy longer lifespans, they become more vulnerable to various health issues, including cancer, similar to humans. This trend creates a growing need for advanced and effective oncology treatments to address these conditions. Consequently, pet owners are more inclined to seek specialized veterinary care, further fueling the demand for services and products within the oncology sector. This heightened awareness around pet health and the willingness to invest in their well-being underscores the expansion and evolution of the veterinary oncology market.

Restraints in the Veterinary Oncology Market

One of the primary challenges facing the veterinary oncology market is the substantial expense associated with cancer treatments, which can present a significant barrier for pet owners. These treatments often encompass a range of services, including diagnostic testing, surgical procedures, medication, and ongoing follow-up care, all of which can accumulate into a considerable financial burden. As a result, the high costs associated with these essential services can restrict the accessibility and affordability of veterinary oncology, ultimately impacting the choices pet owners can make for their beloved animals in times of need. This financial constraint is a prominent issue in the industry.

Market Trends of the Veterinary Oncology Market

The veterinary oncology market is witnessing a significant shift towards personalized medicine, akin to trends in human oncology. This emerging focus prioritizes individualized treatment plans that align with the unique genetic characteristics and biomarker profiles of each animal's cancer. By leveraging advancements in genomics and diagnostics, veterinary oncologists can enhance therapeutic efficacy while reducing adverse effects, ultimately leading to improved patient outcomes. This tailored approach not only fosters a more precise treatment strategy but also aligns with pet owners' increasing expectations for high-quality, customized care for their beloved animals, driving further innovation and investment in the veterinary oncology sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Veterinary Oncology Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
  • Oral Chemotherapy
  • Injectable Chemotherapy
• Radiation Therapy
  • External Beam Radiation Therapy
  • Internal Radiation Therapy
• Immunotherapy
  • Monoclonal Antibodies
  • Cancer Vaccines
• Surgery
  • Tumor Removal
  • Reconstructive Surgery

Global Veterinary Oncology Market Size by Animal Type & CAGR (2026-2033)

• Market Overview
• Companion Animals
  • Dogs
  • Cats
• Livestock Animals
  • Cattle
  • Sheep
  • Pigs

Global Veterinary Oncology Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary And Squamous Cell Cancer
• Others

Global Veterinary Oncology Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Hospitals
• Veterinary Clinics
• Research Institutes
• Others

Global Veterinary Oncology Market Size & CAGR (2026-2033)

• North America (Therapy Type, Animal Type, Cancer Type, End-User)
  • US
  • Canada
• Europe (Therapy Type, Animal Type, Cancer Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Animal Type, Cancer Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Animal Type, Cancer Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Animal Type, Cancer Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heska Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aratana Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accuray Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Morphogenesis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nippon Zenyaku Kogyo Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations